Back to discover

Protein / target

DNA-directed RNA polymerase subunit alpha

rpoAP0A7Z4Escherichia coli (strain K12)Swiss-Prot
30
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

DNA-directed RNA polymerase

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

DNA-dependent RNA polymerase (RNAP) catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.

View complete UniProt function annotation

DNA-dependent RNA polymerase (RNAP) catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. This subunit plays an important role in subunit assembly since its dimerization is the first step in the sequential assembly of subunits to form the holoenzyme

Domains and Gene Ontology detail (19)

Gene Ontology

  • Ccytoplasm
  • Ccytosol
  • CDNA-directed RNA polymerase complex
  • Cmembrane
  • FDNA binding
  • FDNA-directed RNA polymerase activity
  • Fprotein dimerization activity
  • Pbacterial-type flagellum assembly
  • Pbacterial-type flagellum-dependent cell motility
  • Pcell motility
  • Pcellular response to cell envelope stress
  • PDNA-templated transcription initiation

329 aa · 37 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationGOTranscriptional regulationUniProt · GO
View supporting evidence

Cell migration

  • ·cell motility

Transcriptional regulation

  • ·DNA-dependent RNA polymerase (RNAP) catalyzes the transcription of DNA into RNA using th…
  • ·DNA-templated transcription initiation
  • ·regulation of DNA-templated transcription elongation
  • ·regulation of DNA-templated transcription initiation

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 2 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Tuberculosis1 medicine
Tuberculosis, Pulmonary1 medicine

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Rifampin
Inhibitor

Bacterial DNA-directed RNA polymerase inhibitor

Indicated for Tuberculosis, Tuberculosis, Pulmonary

Acts on a complex — shared with rpoB, rpoC, rpoZ · 1 of 4 recorded protein targets

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

NOT_YET_RECRUITING · via Rifampin · NCT07595042

ClinicalTrials.gov via the drug-target graph.

What's happening now

4

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Trial status changed2026-08-25

    Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated Severe Acute Malnutrition

    Status changed to Completed · ClinicalTrials.gov · via Rifampin

  2. Trial results posted2026-08-12

    A Multicenter, Phase 2b/c, Open-label, Randomized, Dose-finding Trial to Evaluate the Safety and Efficacy of a 4 Month Regimen of OPC-167832 in Combination With Delamanid and Bedaquiline in Subjects With Drug-susceptible Pulmonary Tuberculosis in Comparison With Standard Treatment

    Results posted · ClinicalTrials.gov · via Rifampin

  3. Regulatory approval2026-06-29

    Approval: RIFAMPIN (ANDA219918)

    fda · regulatory · fda · via Rifampin

  4. New publication2024-03-28
    Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning.

    BMJ global health · 2024 · 4 citations · Europe PMC · via Rifampin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.